tbuckley/cabot-search huggingface dataset:
Modern Greek Mastery; A Short Road to Ancient Greek.
Authors: Thomas Lathrop Stedman
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-Term Effects of Deferasirox (Exjade®, ICL670) on Serum Ferritin: Outcome of Dose Adjustments in Achieving Maintenance or Reduction in Body Iron Stores.
Authors: J.B. Porter, A. Cohen, L. Agaoglu, A. Ganser, M.D. Cappellini, H. Maseruka, E. Glimm, D. Alberti
Journal: Blood (2006)
British medicine has lessons for North American medicine
Authors: K. Stewart, A. Wagg, M. Kinirons
Journal: BMJ (1995)

EDITOR,—The editorial on futility by Charles Weijer and Carl Elliott had a distinctly North American flavour, which will limit its relevance to British clinicians.1 We do not agree that withdrawing life supporting care from a patient in a persistent vegetative state presents a dilemma; it is common sense to us that such care is futile.

The context in which such decisions are made in North America, or in the United States at least, is …
Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial
Authors: Carmen D Schweighofer, Florence Cymbalista, Carolin Müller, Raymonde Busch, Raphael Porcher, Petra Langerbeins, Bruno Cazin, Anna-Maria Fink, Brigitte Dreyfus, Stefan Ibach, Stéphane Leprêtre, Kirsten Fischer, Ursula Vehling-Kaiser, Barbara Eichhorst, Manuela A. Bergmann, Stephan Stilgenbauer, Hartmut Döhner, Veronique Leblond, Michael Hallek, Vincent Levy
Journal: Blood (2013)
Further Studies on Metastasis of a Transplantable Mouse Mammary Carcinoma after Roentgen Irradiation&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: C.F. Von Essen, H.S. Kaplan
Journal: JNCI Journal of the National Cancer Institute (1952)
A phase II study for selection of clinical and molecular predictors for survival in patients (pts) with advanced NSCLC treated with erlotinib
Authors: U. P. Rohr, A. Rohrbeck, A. Schwalen, S. Kliszewski, R. Haas, R. Kronenwett, R. Kappes, A. Von Haeseler, M. Rosskopf, G. Meckenstock
Journal: Journal of Clinical Oncology (2006)

17066 Background: The primary objective of the ongoing phase II study was to find clinical and molecular predictors for survival. Consequently, we prospectively examined gene and protein expression and EGFR mutation profiles of tumor cells, and clinical variables. Methods: Pts with advanced NSCLC (stage IIIb/IV) previously treated with platinum-based chemotherapy received 150mg/day erlotinib (Tarceva an EGFR tyrosine-kinase inhibitor) orally until disease progression. For molecular analyses, biopsies were taken from the primary lung tumor prior to erlotinib treatment. Pure tumor cells were isolated using laser-capture microdissection. For expression analysis, a microarray of 8793 genes (Human Focus Array, Affymetrix) was used. Data were analyzed using VSN method and significance analysis of microarrays. Results: In an interim analysis, clinical data were available for 36 of 43 so far included pts in the ongoing phase II study. For 36 pts, the tumor responses were: 1 CR (3%), 4 PR (11%), 11 SD (30%) and 19 PD (53%), and the median survival was 20 wks. Overall survival was significantly better in pts with rash than without rash: 9.2 vs 4.3 months. In a 14 months follow up, all of the responding pts survived while the median survival for pts with SD or PD was 11.4 and 4.0 months, respectively. Comparing gene expression profiles of tumors from 6 pts with a response or SD with those from 13 pts with tumor progression, we could not identify genes that were differentially expressed with sufficient significance. In 20 tumor samples evaluated for EGFR protein expression and mutation analysis, 19 expressed EGFR (IHC). A base exchange in exon 18 (2166G&gt;A; A722A) and 20 (2547A&gt;G; Q787Q) of the EGFR already described as a single nucleotide polymorphism was seen in 4 samples performing SSCP gel electrophoresis and sequencing. Conclusions: Rash, a side effect with erlotinib, was significantly associated with better survival. No activating EGFR mutations were found indicating that the response in 14% of pts is independent of mutations. For identification of genes predictive for response to erlotinib, a larger sample number is necessary. No significant financial relationships to disclose.
Abstract 2254: Can Left Atrium Predict Survival After an Acute Coronary Syndrome?
Authors: Rogerio Teixeira, Carolina Lourenco, Natalia Antonio, Rui Baptista, Elisabete Jorge, Silvia Monteiro, Pedro Monteiro, Mario Freitas, Luis A Providencia
Journal: Circulation (2008)

Echocardiography is a crucial tool for the management of the acute coronary syndrome (ACS) patients. To evaluate if left atrium (LA) diameter as a prognostic index in ACS patients. 886 consecutive patients admitted for ACS in a single coronary care unit, between May 2004 and December 2006, and who had echocardiography assessment during admission. Left atrium (LA) diameter was defined by M-Mode paraesternal long axis view. A one-year clinical follow up targeting all-cause mortality was performed. Median age of the population was 66.6±12.2 years, 71.0% were male, and 57.4% were admitted for a non-ST elevation ACS. The area under the operating curve for the LA as a predictor of one year all cause mortality was 0.65 and a cut off of 46 mm had a sensitivity of 67.5% and a specificity of 70.9% for this endpoint. After stratifying the population for this cutoff value of LA diameter, we concluded that patients with a LA diameter ≥ 44mm were older (69.6±11.2 vs 65.3±13.0 years), had a more frequent previous history of, diabetes, dyslipidemia, atrial fibrillation, and a higher body mass index. These patients were more often admitted for an invasive strategy (41.8 vs 32.3% p=0.005), but had a similar coronary anatomy and a similar chance for a complete percutaneous revascularization (49.0 vs 53.0, p=0.37). They had a lower left ventricular ejection fraction (49.6±11.8 vs 52.6±9.6%, p&lt;0.001) higher ventricular dimensions, and presented more often on higher Killip-Kendal classes. There were no associations between LA diameter and LDL cholesterol, admission glycaemia or renal function. In-hospital mortality was similar for both groups (0.3 vs 0.0%, p=0.15), but patients with a LA diameter ≥ 46mm had a one-year survival significantly lower (86.6% vs 94.0%, log rank p &lt; 0.001). This result persisted after an adjusted analysis on a Cox regression model (HR 1.69, 95%CI 1.02 – 2.80 for LA diameter ≥ 44) that included age, gender, diabetes, body mass index and treatment strategy during admission. In our population this simple echocardiographyc parameter was associated with a higher risk profile and worse prognosis on the medium term, and therefore LA diameter should also be included in the global risk assessment of ACS patients.
Abstract 17713: Dyssynchronous Arterial Expansion During Systole as an Early Marker of Vascular Aging: Assessment of Carotid Artery With Velocity Vector Imaging
Authors: Woo-In Yang, Woo-Dae Bang, Hee-Sun Mun, In-Jeong Cho, Min-Kyung Kang, Chi-Young Shim, Yangsoo Jang, Namsik Chung, Jong-Won Ha
Journal: Circulation (2010)

Background:  Pulse wave velocity (PWV) has been known to be useful for the evaluation of arterial stiffness. However, it may represent only global characteristics rather than local vascular alterations. We hypothesized that local vascular properties of carotid artery assessed with velocity vector imaging (VVI) would be more sensitive in the detection of vascular aging compared with PWV.   Methods:  We evaluated 81 healthy, normotensive volunteers (36 male) aged from 20 to 68 years. Transverse images of left common carotid arteries were obtained and divided into six segments. The peak circumferential strain and strain rate of the six segments were analyzed and standard deviation (SD) of the time to peak circumferential strain and strain rate of the six segments, which represent synchronicity of arterial expansion during systole, were calculated.   Results:  PWV and VVI parameters show significant changes with age. However, the age-related changes in PWV and VVI parameters were different. PWV was increasing with age (r=0.62, p   Conclusion:  Arterial assessment using VVI may represent a new method for quantifying vascular alteration noninvasively. Dyssynchronous arterial expansion is a sensitive marker of early arterial aging while PWV would be useful at a ripe old age.   Figure:  Pulse wave velocity and SD of time to peak circumferential strain rate according to age.
Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980
Authors: R. Goldsby, C. Burke, R. Nagarajan, T. Zhou, Z. Chen, P. Inskip, N. Marina, D. Friedman, J. Neglia, S. Bhatia
Journal: Journal of Clinical Oncology (2006)

9007 Background: The growing number of individuals surviving childhood cancer has increased the awareness and recognition of long-term sequelae. One of the most worrisome complications following cancer therapy is the development of second malignant neoplasms (SMN), in particular, late-occurring solid second malignancies related radiation therapy. Methods: We describe the incidence of solid organ SMN in survivors of pediatric malignant bone tumors (MBT) treated on legacy CCG/POG protocols from 1980 to 2005. This retrospective cohort study included 2,842 patients, 1,686 treated for osteosarcoma (OS) and 1,156 treated for Ewings Sarcoma (ES). The cohort included 56% males and 44% females, with a median age at primary diagnosis of 13 years. The median length of follow-up was 4.3 years (range: 0 to 20.9 years). Results: At the time of the analysis, 64% of patients in this study are alive. Seventeen patients with solid organ SMN were identified, and included three patients with breast cancer, three with malignant fibrous histiocytoma, two with osteosarcoma, and 9 patients with other solid organ malignancies. The standardized incidence ratio (SIR=observed/expected cases) was 2.9 (95% confidence interval [CI], 1.4–5.4) for patients treated for OS and 5.0 (95%CI 2.6–9.4) for patients treated for ES. The median time from diagnosis to develop solid organ SMN was 7 years (range: 1 to 13 years). The 10-year cumulative incidence of solid organ SMN for the entire cohort was 1% (95%CI 0.6–2%). In univariate analysis, treatment with etoposide, cyclophosphamide or radiotherapy were each associated with a higher than expected incidence of cancer with SIR of 4.8 (95% CI, 2.5–9.5), 5.8 (95% CI, 3.5–9.5) and 4.1 (95% CI, 2.4–7.1), respectively. Conclusions: Solid organ SMNs are rare after treatment for OS and ES, although higher in patients treated for ES. Recurrence remains the most significant problem for patients diagnosed with MBT and development of improved therapies with fewer long-term consequences remains paramount. However, solid organ cancers are likely to increase with longer follow-up. Therefore, surveillance should focus on monitoring for both recurrence of primary malignancies and development of SMN. No significant financial relationships to disclose.
Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors
Authors: M. N. Stein, A. Tan, K. Taber, R. Fernandez, N. G. Agrawal, E. Vandendries, K. Hsu, A. Walker, K. Holen, G. Wilding
Journal: Journal of Clinical Oncology (2007)

2548 Background: KSP is essential for the separation of spindle poles during mitosis and inhibition results in mitotic arrest. MK- 0731 is a potent inhibitor of KSP, with an IC50 of 2.2 nM, and &gt;20,000 fold selectivity against other kinesins. MK-0731 causes mitotic arrest with an EC50 in several tumor cell lines of 3–5 nM. Methods: Phase I study to determine the safety and tolerability, MTD, and PK of MK-0731 administered IV over 24 hrs every 21 days. In part 1, dosing started at 6 mg/m 2 /24 hr and was escalated until the MTD was reached. In part 2, pts with measurable taxane-resistant cancer were treated at the MTD established in Part 1 (target accrual =22 pts in part 2). Interim Results: 35 pts with solid tumors (M/F 23/12), median age 63 yrs (23 - 79), were treated at doses of 6 to 48 mg/ m 2 /24hrs (median cycles 3, range 1–10, total cycles=128). Frequent tumor types included prostate (8), ovarian (4), colon (3), bladder (2), neuroendocrine (2), lung (2), breast (2). Prolonged (&gt;5 days) grade 4 neutropenia was observed in 2 pts at 48 mg/m2/24hrs (11 days duration) and 2 pts at 24 mg/m2/24hrs (7 days duration) leading to expansion of cohorts at lower dose levels. At the MTD of 17 mg/ m 2 /24, there were no DLTs. 14 patients have been enrolled at the MTD in part 2 of the study. Drug related grade 3/4 toxicities were anemia (1), AST (1), hyperglycemia (1), nausea/vomiting (1), neutropenia (7), syncope (1). PK results from the first 20 patients suggest that MK- 0731 concentrations appear to decline monoexponentially or biexponentially following the infusion with terminal t1/2 from ∼4 to 22 hrs. In some patients, steady-state concentrations may not be achieved by the end of the 24 hr infusion. Mean values at the 17 mg/m2/24hrs dose level were Cmax=599 nM, AUC8=14.56 μM·hr, and CL=119 mL/min. AUC, exposures, and end of infusion concentrations appear to increase proportionally with dose. Stable disease for = 4 cycles (range 4- 10) was seen in 16 patients. Conclusion: Treatment with MK-0731 at the MTD of 17 mg/m 2 /day every 21 days in patients with advanced solid tumors was well tolerated with consistent dose limiting toxicity of myelosuppression. No significant financial relationships to disclose.
Vaccines for Sexually Transmitted Diseases
Authors: A. Meheus, R. E. Spier
Journal: Annals of Internal Medicine (1990)

Part 1 Introduction: epidemiology immunological principles of vaccine design selection and suitability of adjuvants. Part 2 Gonorrhoea and candidiasis: problems and prospects for the development of a vaccine against gonorrhoea serum and vaginal fluid antibodies against the gonococcal major iron-regulated protein in women with pelvic inflamatory disease or uncomplicated infection D.651, an oral vaccine for the prevention of vulvovaginal candidiasis preparation and characterization of pilin synthetic peptide-MIRP conjugates as a potential vaccine for the prevention of gonococcal infections specificity of serum immunoglobulin G subclass response to gonorrhoea in women molecular biology of gonococcal porim protein P.I. Part 3 Chlamydia: immunity to chlamydial infections prevention of pulmonary and genital  infection by oral immunization stability and safety of a chlamydial live vaccine against enzootic abortion of ewes passive transfer experiments to study the protection against chlamydia psittaci infection of the mouse lymphocyte proliferation response to chlamydial antigens in human ocular chlamydial infections production and immunoanalysis of recombinant E. Trachomatis serovar D major outer membrane protein (MOMP). Part 4: Syphilis experimental syphilis vaccines - use of aroA salmonella typhimurium to deliver recombinant treponema pallidum antigens cellular and molecular approaches to the development of a vaccine for syphilis. Part 5 Hepatitis B: current and future hepatitis B vaccines development and clinical studies with a recombinant DNA hepatitis B vaccine ISCOMs (immune-stimulating complexes) and the presentation of HBsAg peptides. Part 6 Papillomaviruses: a vaccine to genital papillomaviruses - is it feasible? vaccination against polyoma - and papillomavirus-induced tumours using vaccinia recombinants expressing non-structural proteins. Part 7 Herpes simplex: Herpes simplex vaccines development of an HSV subunit vaccine poor immunogenicity as the reasons for the ineffectiveness of a glycoprotein subunit vaccine for genital herpes efficacy of yeast-derived glycoprotein B of herpes simplex virus on the development of herpetic lesion after intravaginal challenge with HSV type 2 follow-up report on 101 subjects vaccinated with Skinner herpes vaccine the development of a subunit cytomegalovirus vaccine effect of HSV-1 antigen preparations derived using a Zwitterionic detergent on HSV-1 latency using a mouse model characterization of an HSV-1 subunit vaccine and its enhanced immunogenicity in the form of an immunostimulating comples (HSV-1 ISCOM) preparation (Part contents)
Basic Biology of Man
Authors: G. Kasten Tallmadge
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CLINICAL STUDIES ON VERODIGEN, A DIGITALIS GLUCOSIDE
Authors: J. P. BAKER, M.D., NATHAN BLOOM, M.D.
Journal: Annals of Internal Medicine (1936)

ExcerptVerodigen, a gitalin-like fraction of digitalis, has been used for a number of years in several European countries, and in some instances has largely replaced the galenical preparations of digitalis. There have been a number of reports on its usefulness,1, 2, 3which give the impression that it is considered superior to digitalis in several ways. From a clinical standpoint, it is said to be absorbed more readily and to exert its effect on the heart more rapidly than digitalis. It is claimed, moreover, that this drug is borne by the gastrointestinal tract better, causing nausea and vomiting less often...
Elemental Constituents of Particulate Matter and Newborn’s Size in Eight European Cohorts
Authors: Marie Pedersen, Ulrike Gehring, Rob Beelen, Meng Wang, Lise Giorgis-Allemand, Anne-Marie Nybo Andersen, Xavier Basagaña, Claire Bernard, Marta Cirach, Francesco Forastiere, Kees de Hoogh, Olena Gruzieva, Gerard Hoek, Aleksandra Jedynska, Claudia Klümper, Ingeborg M. Kooter, Ursula Krämer, Jaakko Kukkonen, Daniela Porta, Dirkje S. Postma, Ole Raaschou-Nielsen, Lenie van Rossem, Jordi Sunyer, Mette Sørensen, Ming-Yi Tsai, Tanja G. M. Vrijkotte, Michael Wilhelm, Mark J. Nieuwenhuijsen, Göran Pershagen, Bert Brunekreef, Manolis Kogevinas, Rémy Slama
Journal: Environmental Health Perspectives (2015)

BackgroundThe health effects of suspended particulate matter (PM) may depend on its chemical composition. Associations between maternal exposure to chemical constituents of PM and newborn's size have been little examined.ObjectiveWe aimed to investigate the associations of exposure to elemental constituents of PM with term low birth weight (LBW; weight < 2,500 g among births after 37 weeks of gestation), mean birth weight, and head circumference, relying on standardized fine-scale exposure assessment and with extensive control for potential confounders.MethodsWe pooled data from eight European cohorts comprising 34,923 singleton births in 1994–2008. Annual average concentrations of elemental constituents of PM ≤ 2.5 and ≤ 10 μm (PM2.5 and PM10) at maternal home addresses during pregnancy were estimated using land-use regression models. Adjusted associations between each birth measurement and concentrations of eight elements (copper, iron, potassium, nickel, sulfur, silicon, vanadium, and zinc) were calculated using random-effects regression on pooled data.ResultsA 200-ng/m3 increase in sulfur in PM2.5 was associated with an increased risk of LBW (adjusted odds ratio = 1.36; 95% confidence interval: 1.17, 1.58). Increased nickel and zinc in PM2.5 concentrations were also associated with an increased risk of LBW. Head circumference was reduced at higher exposure to all elements except potassium. All associations with sulfur were most robust to adjustment for PM2.5 mass concentration. All results were similar for PM10.ConclusionSulfur, reflecting secondary combustion particles in this study, may adversely affect LBW and head circumference, independently of particle mass.CitationPedersen M, Gehring U, Beelen R, Wang M, Giorgis-Allemand L, Andersen AM, Basagaña X, Bernard C, Cirach M, Forastiere F, de Hoogh K, Gražulevičienė R, Gruzieva O, Hoek G, Jedynska A, Klümper C, Kooter IM, Krämer U, Kukkonen J, Porta D, Postma DS, Raaschou-Nielsen O, van Rossem L, Sunyer J, Sørensen M, Tsai MY, Vrijkotte TG, Wilhelm M, Nieuwenhuijsen MJ, Pershagen G, Brunekreef B, Kogevinas M, Slama R. 2016. Elemental constituents of particulate matter and newborn's size in eight European cohorts. Environ Health Perspect 124:141–150; http://dx.doi.org/10.1289/ehp.1409546
851. Influence of Factor X on In Vitro and In Vivo Gene Delivery by Ad5 and Ad35 Vectors
Authors: Jenny A. Greig, Suzanne M. K. Buckley, Simon N. Waddington, Alan L. Parker, D. Bhella, R. Pink, T. Morita, Jerome Custers, J. Goudsmit, Stuart A. Nicklin, John H. Mcvey, Andrew H. Baker
Journal: Molecular Therapy (2009)